BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

Colorectal cancer (CRC) is one of the most common malignant cancers and its incidence is steadily rising particularly in ...

Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In ...

With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for ...

Colon cancer pain can happen in later stages of the condition as a tumor grows larger. Symptoms include pain in the abdomen ...

A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an ...

Their new findings on later-stage disease suggest that as well as reducing sugary drinks, targeting the SORD enzyme may offer opportunities to reduce colorectal cancer spread. Making revisions to ...

Liver transplant improved progression-free survival (PFS) in carefully selected patients with unresectable colorectal liver metastasis; however, the overall survival and recurrence rate benefits did ...

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus ...